Vivani Provides Business Update and Reports Q4 and FY23 Financial Results
Vivani Medical Appoints Daniel Bradbury to its Board of Directors
Vivani Medical Announces Pricing of $15.0 Million Registered Direct Offering
New data suggest Vivani’s miniature exenatide implant, NPM-115, works as well as Novo Nordisk’s Wegovy and Ozempic for weight loss in mice. The implant delivers high doses of exenatide, a GLP-1 receptor agonist commercialized by AstraZeneca as Bydureon for treating Type 2 diabetes.
Vivani Medical Announces Positive NPM-115 Preclinical Weight Loss Data
Vivani Provides Business Update and Reports Third Quarter Financial Results
Vivani Medical to Present at BIO Investor Forum
Vivani Medical to Present at the Boulder Peptide Symposium
Vivani Medical Subsidiary Cortigent to Present Orion Clinical Study Results at The Eye and The Chip World Research Congress on Artificial Vision October 8-10
Vivani Medical Reports Second Quarter Financial Results and Provides Business Update